About Tirzepatide Legal | Research Digest

About this site

Tirzepatide Legal is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide — the FDA-approved dual GIP/GLP-1 receptor agonist.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — trial records, FDA labeling, pharmacovigilance databases, and peer-reviewed journal publications.

The domain modifier "legal" is an editorial framing: this site focuses on the regulatory and legal-status record — the approval timeline, the labeled indications, the boxed warnings, and the safety signals documented in the trial and post-market literature. It does not provide legal counsel, regulatory advice, or medical guidance.

Why a dedicated reference site on tirzepatide? The peer-reviewed evidence base for this drug is large and growing. The SURPASS and SURMOUNT clinical programmes together span more than a dozen randomized controlled trials with tens of thousands of participants, and beyond-glycemia evidence continues to emerge from dedicated trials in heart failure, sleep apnea, and liver disease. That record deserves a plain, accurate, cited summary accessible to general readers — not promotional, not adversarial, just the documented science.

Every quantitative claim on this site is cited to a specific published source. Every citation carries a DOI or PubMed URL. The reference list is on the Tirzepatide references page.

This site does not make dosing recommendations. It describes what was studied in which population, at which doses, with which outcomes — and it identifies the approved indications and labeled warnings from the FDA prescribing information. Nothing here constitutes medical advice.